265 related articles for article (PubMed ID: 25265432)
21. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
22. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
Krämer A; Schultheis B; Bergmann J; Willer A; Hegenbart U; Ho AD; Goldschmidt H; Hehlmann R
Leukemia; 2002 Sep; 16(9):1844-51. PubMed ID: 12200702
[TBL] [Abstract][Full Text] [Related]
23. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.
Wlodarska I; Dierickx D; Vanhentenrijk V; Van Roosbroeck K; Pospísilová H; Minnei F; Verhoef G; Thomas J; Vandenberghe P; De Wolf-Peeters C
Blood; 2008 Jun; 111(12):5683-90. PubMed ID: 18391076
[TBL] [Abstract][Full Text] [Related]
24. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
25. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
26. Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.
Ma Y; Feng Q; Sekula D; Diehl JA; Freemantle SJ; Dmitrovsky E
Cancer Res; 2005 Jul; 65(14):6476-83. PubMed ID: 16024653
[TBL] [Abstract][Full Text] [Related]
27. Expression of cyclin genes in human gastric cancer and in first degree relatives.
Yu J; Miehlke S; Ebert MP; Szokodi D; Wehvnignh B; Malfertheiner P; Ehninger G; Bayerdoerffer E
Chin Med J (Engl); 2002 May; 115(5):710-5. PubMed ID: 12133540
[TBL] [Abstract][Full Text] [Related]
28. D-type cyclins in adult human testis and testicular cancer: relation to cell type, proliferation, differentiation, and malignancy.
Bartkova J; Rajpert-de Meyts E; Skakkebaek NE; Bartek J
J Pathol; 1999 Apr; 187(5):573-81. PubMed ID: 10398124
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
31. Deregulation of D-type cyclins in uterine cancers. Cyclin D1/D3 is differentially expressed in cervical cancer.
Skomedal H; Forus A; Holm R
Anticancer Res; 2003; 23(5A):3929-35. PubMed ID: 14666699
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
[TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
34. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth.
Kushner JA; Ciemerych MA; Sicinska E; Wartschow LM; Teta M; Long SY; Sicinski P; White MF
Mol Cell Biol; 2005 May; 25(9):3752-62. PubMed ID: 15831479
[TBL] [Abstract][Full Text] [Related]
35. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
36. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo.
Mullany LK; White P; Hanse EA; Nelsen CJ; Goggin MM; Mullany JE; Anttila CK; Greenbaum LE; Kaestner KH; Albrecht JH
Cell Cycle; 2008 Jul; 7(14):2215-24. PubMed ID: 18635970
[TBL] [Abstract][Full Text] [Related]
37. Cyclin D1 expression in patients with multiple myeloma.
Troussard X; Avet-Loiseau H; Macro M; Mellerin MP; Malet M; Roussel M; Sola B
Hematol J; 2000; 1(3):181-5. PubMed ID: 11920187
[TBL] [Abstract][Full Text] [Related]
38. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of cell cycle regulatory proteins in benign and malignant bone and soft tissue neoplasms.
Bui MM; Bagui TK; Boulware DC; Letson DG; Nasir A; Kaiser HE; Pledger WJ; Coppola D
In Vivo; 2007; 21(5):729-37. PubMed ID: 18019405
[TBL] [Abstract][Full Text] [Related]
40. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.
Takano Y; Kato Y; Masuda M; Ohshima Y; Okayasu I
J Pathol; 1999 Oct; 189(2):194-200. PubMed ID: 10547574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
